Navigation Links
VIRxSYS Announces Interim Results from VRX496 Gene Therapy Phase II Trial
Date:2/6/2008

al vectors, lentiviral vectors appear to sustain expression of the delivered genes of interest for a longer period of time. Their safety profiles are currently being evaluated in clinical trials.

"These results are everything we've been hoping for," said Dr. Riku Rautsola, CEO and President of VIRxSYS. "VRX496 is a remarkably promising treatment for HIV. We are very excited about what we are seeing so far in our trials and are confident that these results will continue into Phase III."

The VIRxSYS results were presented at CROI on Tuesday, February 5th from 1-4 PM at session 124 in Hall A. The VIRxSYS poster was number 753.

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which has advanced to Phase 2 human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

Contact: Paul Gibney

Phone: (212) 255-5340

E-mail: pgibney@corinthgroup.com


'/>"/>
SOURCE VIRxSYS Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIRxSYS and Lentigen Announce Litigation Settlement
2. Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
3. Global Probiotics Council Announces Young Investigator Grant for Probiotics Research to Fund the Next Generation of Gut Microbiota Research
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. Xenon Announces Appointment of VP, Discovery Research
7. BioSpecifics Technologies Corp. Announces Repayment of Outstanding Loan
8. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
9. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
10. DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results
11. Physicians Reference Laboratory Announces New Diagnostic for Womens Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Francisco, California (PRWEB) October 01, 2014 ... from the National Science Foundation to expand their bioCAD/CAM ... to build and modify DNA. The Small Business Innovation ... commercialize the “j5” technology under exclusive license from the ... Joint BioEnergy Institute , an LBNL laboratory that ...
(Date:9/30/2014)... a well-known optical phenomenon called thin-film interference, a ... the ability to "paint" ultra-thin coatings onto a ... making future, flexible electronic devices, creating advanced solar ... ships and spacecraft with extremely lightweight decorative logos. ... it becomes iridescent, revealing a myriad of colors ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released ... highly precise tool for measuring displacement in rubber ... 1000-mm maximum movement distance, the DSES-1000 can measure ... length of 10 mm. In addition, it achieves ... stroke and within +/- 100 µm below 50-mm ...
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
Breaking Biology Technology:TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2
... 19, 2011 New Report Added in ... to 2020 - Programmable Logic Devices (PLD) and Application Specific ...   Published by  GBI Research . ... 2020 Programmable Logic Devices (PLD) and Application Specific Standard Product ...
... about how certain kinds of bacteria make energy and synthesize ... team of scientists led by Donald Bryant, the Ernest C. ... research professor in the Department of Chemistry and Biochemistry at ... the journal Science on 16 December 2011, is ...
... The efficiency of conventional solar cells could be ... of solar energy conversion led by chemist Xiaoyang Zhu ... and his team have discovered that it,s possible to ... of sunlight using an organic plastic semiconductor material. ...
Cached Biology Technology:ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 2Decades-old conclusion about energy-making pathway of cyanobacteria is corrected 3Discovery of a 'dark state' could mean a brighter future for solar energy 2
(Date:9/30/2014)... Researchers of Ludwig-Maximilians-Universitaet (LMU) in Munich report that ... cells more sensitive to chemotherapeutic drugs. They have ... a new target for anti-tumor agents. , ... Professor Stephan Sieber of the Technische Universitt Mnchen ... a potential new weapon in the fight against ...
(Date:9/30/2014)... in German . ... to risky situations such as exposure to predators. Researchers ... in a long-term study on different populations of great ... and ambient temperature. High metabolic rates and low temperatures ... scenarios birds were more likely to approach potential predators. ...
(Date:9/30/2014)... People who suffer from asthma may think there,s ... asthma besides properly taking medications and avoiding allergic triggers. ... Annals of Allergy, Asthma and Immunology , the ... and Immunology (ACAAI), asthma sufferers can learn lessons about ... described in the Annals article improved her asthma once ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Risky metabolism 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... On Monday, August 17th at 1:30PM in Hensill Hall 113, ... AAAS in San Francisco will get to learn about the ... minds in the field. The symposium is called Good ... the Public. (Online link: http://www.sou.edu/aaaspd/2009SANFRANCISCO/Symposia09.html#15 ). As science ...
... another piece to the mounting body of evidence that ... arrest, "passive ventilation" significantly increases survival rates, compared to ... in an online edition of Annals of Emergency Medicine, ... cardiac arrest outside a hospital setting and were resuscitated ...
... 12, 2009) Research published online in the journal ... are associated with a 2.5-fold reduction in risk for neural ... brain and spinal cord, and the two most common NTDs ... Disease Control (CDC), an estimated 3,000 pregnancies in the U.S. ...
Cached Biology News:Science communication to take the stage at annual AAAS meeting in San Francisco 2Cardiac arrest resuscitation: Passive oxygen flow better than assisted ventilation 2Essential nutrient found in eggs may help lower risk of neural tube defects 2Essential nutrient found in eggs may help lower risk of neural tube defects 3
... pp65 Antigenemia Immunofluorescence Assay (IFA) is intended ... protein pp65 of CMV in isolated peripheral ... Erythrocyte Lysis Buffer - (Catalog ... of buffered ammonium chloride. (NH4CL) Fixation ...
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... samples for freezing point determinations. Includes built-in printer, keypad, and software for ... RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Biology Products: